Re:FDA advisors unanimously vote to approve Moderna's mRNA a...
by oatmeal1 on Tuesday June 23, 2026 @01:31AM
(#48640720)
You identify the potential bias of only one side here. The revolving door between regulators and industry introduces potential biases of others in the opposite direction.
If Prasad approved of the trial design and later decided it was insufficient then I would see things differently.
If Prasad approved of the trial design and later decided it was insufficient then I would see things differently.